Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (271-280 of 566) with videos related to

Pageof 57
Sort By:
Blood|November 3, 2007
Improved survival in multiple myeloma and the impact of novel therapiesShaji K Kumar, S Vincent Rajkumar, Angela Dispenzieri, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Leukemia & Lymphoma|April 11, 2015
Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and bothLadan Zand, Samih H Nasr, Morie A Gertz, et al.
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
Leukemia|September 12, 2018
Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristicsAlyssa I Clay-Gilmour, Shaji Kumar, S Vincent Rajkumar, et al.
British Journal of Haematology|August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myelomaRuben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.
Blood Cancer Journal|August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigmCharlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
Kidney International Reports|May 2, 2022
Kidney Transplant Outcomes of Patients With Multiple MyelomaCihan Heybeli, Andrew J Bentall, Mariam Priya Alexander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2021
The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple MyelomaNeeraj Sharma, James B Smadbeck, Nadine Abdallah, et al.
Blood Cancer Journal|September 23, 2021
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)Matthew Ho, Saurabh Zanwar, Prashant Kapoor, et al.
Pageof 57

Showing results (271-280 of 566) with videos related to

Sort By:
Pageof 57
Blood|November 3, 2007
Improved survival in multiple myeloma and the impact of novel therapiesShaji K Kumar, S Vincent Rajkumar, Angela Dispenzieri, et al.
Leukemia|January 31, 2019
Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenanceShaji K Kumar, Jesus G Berdeja, Ruben Niesvizky, et al.
Leukemia & Lymphoma|April 11, 2015
Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and bothLadan Zand, Samih H Nasr, Morie A Gertz, et al.
Blood Cancer Journal|October 6, 2018
Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working GroupLia A Moulopoulos, Vassilis Koutoulidis, Jens Hillengass, et al.
Leukemia|September 12, 2018
Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristicsAlyssa I Clay-Gilmour, Shaji Kumar, S Vincent Rajkumar, et al.
British Journal of Haematology|August 5, 2008
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myelomaRuben Niesvizky, Paul G Richardson, S Vincent Rajkumar, et al.
Blood Cancer Journal|August 12, 2024
Progression-free survival as a surrogate endpoint in myeloma clinical trials: an evolving paradigmCharlotte Pawlyn, Fredrik H Schjesvold, David A Cairns, et al.
Kidney International Reports|May 2, 2022
Kidney Transplant Outcomes of Patients With Multiple MyelomaCihan Heybeli, Andrew J Bentall, Mariam Priya Alexander, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2021
The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple MyelomaNeeraj Sharma, James B Smadbeck, Nadine Abdallah, et al.
Blood Cancer Journal|September 23, 2021
The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)Matthew Ho, Saurabh Zanwar, Prashant Kapoor, et al.
Pageof 57